Jump Financial LLC Invests $362,000 in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Jump Financial LLC purchased a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in the 4th quarter, HoldingsChannel reports. The fund purchased 16,240 shares of the biopharmaceutical company’s stock, valued at approximately $362,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Agios Pharmaceuticals by 25.7% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,502 shares of the biopharmaceutical company’s stock worth $260,000 after buying an additional 2,148 shares during the period. Teacher Retirement System of Texas increased its holdings in shares of Agios Pharmaceuticals by 5.3% in the 3rd quarter. Teacher Retirement System of Texas now owns 15,770 shares of the biopharmaceutical company’s stock valued at $390,000 after purchasing an additional 788 shares during the period. Principal Financial Group Inc. lifted its position in shares of Agios Pharmaceuticals by 19.2% in the third quarter. Principal Financial Group Inc. now owns 16,188 shares of the biopharmaceutical company’s stock worth $401,000 after purchasing an additional 2,609 shares in the last quarter. Swiss National Bank boosted its holdings in shares of Agios Pharmaceuticals by 1.5% during the third quarter. Swiss National Bank now owns 122,160 shares of the biopharmaceutical company’s stock worth $3,023,000 after purchasing an additional 1,800 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in Agios Pharmaceuticals by 3.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 451,695 shares of the biopharmaceutical company’s stock valued at $11,179,000 after purchasing an additional 14,420 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. Royal Bank of Canada lowered their price target on shares of Agios Pharmaceuticals from $43.00 to $42.00 and set an “outperform” rating on the stock in a report on Friday, February 16th. StockNews.com lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday. The Goldman Sachs Group lifted their price target on Agios Pharmaceuticals from $29.00 to $33.00 and gave the company a “neutral” rating in a report on Friday, May 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, April 9th. Finally, JPMorgan Chase & Co. decreased their target price on shares of Agios Pharmaceuticals from $31.00 to $30.00 and set a “neutral” rating for the company in a research report on Friday, February 23rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat, Agios Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $35.00.

Insiders Place Their Bets

In related news, insider James William Burns sold 2,642 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $32.57, for a total value of $86,049.94. Following the transaction, the insider now owns 34,518 shares in the company, valued at $1,124,251.26. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CEO Brian Goff sold 4,156 shares of the stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $32.57, for a total transaction of $135,360.92. Following the completion of the sale, the chief executive officer now owns 53,780 shares of the company’s stock, valued at $1,751,614.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider James William Burns sold 2,642 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $32.57, for a total value of $86,049.94. Following the completion of the sale, the insider now directly owns 34,518 shares in the company, valued at approximately $1,124,251.26. The disclosure for this sale can be found here. Insiders have sold a total of 14,889 shares of company stock valued at $445,716 in the last 90 days. 4.93% of the stock is currently owned by insiders.

Agios Pharmaceuticals Trading Down 3.6 %

Shares of AGIO stock opened at $31.50 on Friday. The stock has a 50 day moving average of $31.15 and a two-hundred day moving average of $26.90. The company has a market capitalization of $1.79 billion, a P/E ratio of -4.98 and a beta of 0.81. Agios Pharmaceuticals, Inc. has a 12 month low of $19.80 and a 12 month high of $35.50.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.65) by $0.20. The business had revenue of $8.19 million during the quarter, compared to analysts’ expectations of $8.37 million. Agios Pharmaceuticals had a negative return on equity of 41.41% and a negative net margin of 1,199.26%. Agios Pharmaceuticals’s quarterly revenue was up 46.0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.47) EPS. Sell-side analysts predict that Agios Pharmaceuticals, Inc. will post -4.6 earnings per share for the current fiscal year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.